keyword
MENU ▼
Read by QxMD icon Read
search

breast cancer neoadjuvant treatment

keyword
https://www.readbyqxmd.com/read/28438694/predictive-role-of-gstp1-containing-exosomes-in-chemotherapy-resistant-breast-cancer
#1
Su-Jin Yang, Dan-Dan Wang, Jian Li, Han-Zi Xu, Hong-Yu Shen, Xiu Chen, Si-Ying Zhou, Shan-Liang Zhong, Jian-Hua Zhao, Jin-Hai Tang
Anthracycline/taxane-based chemotherapy regimens are usually used as neoadjuvant chemotherapies to decrease tumour size and prevent metastasis of advanced breast cancer. However, patients have a high risk of developing chemo-resistance during treatment through still unknown mechanisms. Glutathione S-transferase P1 (GSTP1), which belongs to the family of phase II metabolic enzymes, has been reported to function in detoxifying several anti-cancer drugs by conjugating them with glutathione. Previous studies have identified GSTP1 as a predictor of prognosis and chemo-resistance in breast cancer patients, but the mechanisms governing GSTP1-dependent drug resistance are still unclear...
April 21, 2017: Gene
https://www.readbyqxmd.com/read/28432515/mri-predicts-pathologic-complete-response-in-her2-positive-breast-cancer-after-neoadjuvant-chemotherapy
#2
Mette S van Ramshorst, Claudette E Loo, Emilie J Groen, Gonneke H Winter-Warnars, Jelle Wesseling, Frederieke van Duijnhoven, Marie-Jeanne T Vrancken Peeters, Gabe S Sonke
BACKGROUND: Neoadjuvant treatment of HER2-positive breast cancer frequently leads to a pathologic complete response (pCR), which is associated with favourable long-term outcome. Treatment regimens typically consist of 6-9 cycles of trastuzumab-based chemotherapy, although many patients achieve early radiologic complete response (rCR). If rCR accurately predicts pCR, the number of chemotherapy cycles can possibly be reduced. METHODS: We performed a diagnostic accuracy study to determine the association between rCR and pCR in patients with stage II-III HER2-positive breast cancer treated with neoadjuvant trastuzumab-based chemotherapy at the Netherlands Cancer Institute...
April 21, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28425345/surrogate-marker-analysis-in-cancer-clinical-trials-through-time-to-event-mediation-techniques
#3
Sjouke Vandenberghe, Luc Duchateau, Leen Slaets, Jan Bogaerts, Stijn Vansteelandt
The meta-analytic approach is the gold standard for validation of surrogate markers, but has the drawback of requiring data from several trials. We refine modern mediation analysis techniques for time-to-event endpoints and apply them to investigate whether pathological complete response can be used as a surrogate marker for disease-free survival in the EORTC 10994/BIG 1-00 randomised phase 3 trial in which locally advanced breast cancer patients were randomised to either taxane or anthracycline based neoadjuvant chemotherapy...
January 1, 2017: Statistical Methods in Medical Research
https://www.readbyqxmd.com/read/28424130/invasive-pleomorphic-lobular-histology-is-an-adverse-prognostic-factor-on-survival-in-patients-with-breast-cancer
#4
Suleyman Sahin, Fatih Karatas, Gokmen U Erdem, Bekir Hacioglu, Kadri Altundag
Invasive pleomorphic lobular carcinoma (IPLC) is defined to be an uncommon and different subtype of classical invasive lobular carcinoma (ILC). This special variant is characterized by significant cytological atypia and pleomorphism which differs from the cytological uniformity of ILC. IPLC has been shown to have some poor prognostic factors such as axillary node metastasis and higher histological grade which may lead to poor clinical courses including a short relapse time, increased risk of recurrence and a decreased survival...
April 1, 2017: American Surgeon
https://www.readbyqxmd.com/read/28419079/predicting-breast-cancer-response-to-neoadjuvant-chemotherapy-using-pretreatment-diffuse-optical-spectroscopic-texture-analysis
#5
William T Tran, Mehrdad J Gangeh, Lakshmanan Sannachi, Lee Chin, Elyse Watkins, Silvio G Bruni, Rashin Fallah Rastegar, Belinda Curpen, Maureen Trudeau, Sonal Gandhi, Martin Yaffe, Elzbieta Slodkowska, Charmaine Childs, Ali Sadeghi-Naini, Gregory J Czarnota
BACKGROUND: Diffuse optical spectroscopy (DOS) has been demonstrated capable of monitoring response to neoadjuvant chemotherapy (NAC) in locally advanced breast cancer (LABC) patients. In this study, we evaluate texture features of pretreatment DOS functional maps for predicting LABC response to NAC. METHODS: Locally advanced breast cancer patients (n=37) underwent DOS breast imaging before starting NAC. Breast tissue parametric maps were constructed and texture analyses were performed based on grey-level co-occurrence matrices for feature extraction...
April 18, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28416193/lep-rs7799039-lepr-rs1137101-and-adipoq-rs2241766-and-1501299-polymorphisms-are-associated-with-obesity-and-chemotherapy-response-in-mexican-women-with-breast-cancer
#6
Alejandra Méndez-Hernández, Martha Patricia Gallegos-Arreola, Hortensia Moreno-Macías, Jorge Espinosa Fematt, Rebeca Pérez-Morales
BACKGROUND: Obesity plays a major role in the pathogenesis of breast cancer. Leptin (LEP) and adiponectin (ADIPOQ) are important in the regulation of adipose tissue. The response to cancer treatment depends on the histological and molecular tumor type, clinical stage, and genetic variability that might promote carcinogenic development. The aim of this study was to investigate the association between overweight/obesity and polymorphisms in the LEP (rs7799039), LEP receptor (LEPR; rs1137101), and ADIPOQ genes (rs2241766, rs1501299) with the response to breast cancer treatment in Mexican women...
March 22, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28412725/immunohistochemical-ki67-after-short-term-hormone-therapy-identifies-low-risk-breast-cancers-as-reliably-as-genomic-markers
#7
Takayuki Iwamoto, Toyomasa Katagiri, Naoki Niikura, Yuichiro Miyoshi, Mariko Kochi, Tomohiro Nogami, Tadahiko Shien, Takayuki Motoki, Naruto Taira, Masako Omori, Yutaka Tokuda, Toshiyoshi Fujiwara, Hiroyoshi Doihara, Balazs Gyorffy, Junji Matsuoka
BACKGROUND: The purpose of this study was to test whether immunohistochemical (IHC) Ki67 levels after short-term preoperative hormone therapy (post-Ki67) predict similar numbers of patients with favorable prognoses as genomic markers. RESULTS: Thirty paired cases (60 samples) were enrolled in this study. Post-Ki67 levels were significantly lower than pre-treatment Ki67 levels (P < 0.001). Post-Ki67 predicted more low-risk cases (83.3%, 25/30) than pre-genomic surrogate signature(GSS) (66...
February 16, 2017: Oncotarget
https://www.readbyqxmd.com/read/28411682/update-on-preoperative-breast-localization
#8
REVIEW
Mary K Hayes
The radiologist plays an important role in detection, diagnosis, localization, pathologic correlation, and follow-up imaging of breast cancer. A successful breast surgical treatment program relies on the image guidance tools and skills of the radiologist and surgeon. This article reviews the evolving tools available for preoperative localization. Non-wire devices provide a safe, efficient, noninferior alternative to wire localization and can be placed 0 to 30 days before scheduled surgery. This technology may evolve to other longer-term, efficient, and cost-effective applications for patients who require neoadjuvant treatment or who have findings visible only at MR imaging...
May 2017: Radiologic Clinics of North America
https://www.readbyqxmd.com/read/28411447/making-progress-in-early-breast-cancer-taking-time-or-accepting-risk
#9
Gurdeep S Mannu, David Dodwell
Outcomes for patients diagnosed with early breast cancer in developed countries have improved substantially over recent decades. Adjuvant therapies have contributed to this improvement and their benefits have been confirmed in large randomised controlled trials (RCTs) and meta-analyses. Lower event rates, whilst welcome, have created problems for RCTs, that need to be larger and often take longer to provide a reliable result. In an effort to maintain the rate of progress and to obviate the complexity, cost and time required to conduct large RCTs, there has been an increased tendency to rely on observational data to determine a treatment effect and also to accelerate progress by the use of a surrogate marker (pathological complete remission after neoadjuvant chemotherapy)...
April 12, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28407247/using-the-21-gene-assay-from-core-needle-biopsies-to-choose-neoadjuvant-therapy-for-breast-cancer-a-multicenter-trial
#10
Harry D Bear, Wen Wan, André Robidoux, Peter Rubin, Steven Limentani, Richard L White, James Granfortuna, Judith O Hopkins, Dwight Oldham, Angel Rodriguez, Amy P Sing
OBJECTIVE: We hypothesized that the Oncotype Dx(®) 21-gene Recurrence Score (RS) could guide neoadjuvant systemic therapy (NST) to facilitate breast conserving surgery (BCS) for hormone receptor positive (HR+) breast cancers. METHODS: This study enrolled patients with HR+, HER2-negative, invasive breast cancers not suitable for BCS (size ≥ 2 cm). Core needle biopsy blocks were tested. For tumors with RS < 11, patients received hormonal therapy (NHT); patients with RS > 25 tumors received chemotherapy (NCT); patients with RS 11-25 were randomized to NHT or NCT...
April 13, 2017: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28403971/-performances-of-breast-magnetic-resonance-imaging-in-the-context-of-neoadjuvant-chemotherapy-for-breast-cancer-to-predict-pathological-complete-response
#11
C Brisson, C Diguisto, A Vildé, G Body, F Arbion, J Leveque, L Ouldamer
PURPOSE: The objective of this work was to estimate the reliability of MRI after neoadjuvant chemotherapy (NAC) for breast cancer to detect a residual tumour by comparing the tumoral size measured by MRI with the histological size. We also estimated the concordance of diagnosis of complete pathological response between histological examination and MRI. MATERIALS AND METHODS: We included all the patients who received a neoadjuvant chemotherapy for breast cancer in the university hospital of Tours from January, 2008 to December 31st, 2012 and in the comprehensive cancer centre of Rennes from January, 2008 till May 31st 201...
February 2017: J Gynecol Obstet Hum Reprod
https://www.readbyqxmd.com/read/28402606/timing-of-paclitaxel-treatment-in-pre-operative-or-post-operative-does-not-affect-survival-in-breast-cancer-patients
#12
Jiayu Wang, Shanshan Chen, Binghe Xu, Peng Yuan, Fei Ma, Qing Li, Pin Zhang, Ruigang Cai, Ying Fan, Yang Luo, Qiao Li
BACKGROUND: Two epirubicin and paclitaxel-based neoadjuvant chemotherapy regimens were compared in breast cancer patients. METHODS: We enrolled 309 breast cancer patients who received two types of regimens: cyclophosphamide + epirubicin dose-dense neoadjuvant chemotherapy followed by sequential postoperative paclitaxel single-drug medication, and paclitaxel + epirubicin standard neoadjuvant chemotherapy followed by two cycles of the same chemotherapy after surgery...
April 12, 2017: Thoracic Cancer
https://www.readbyqxmd.com/read/28391512/is-regression-after-neoadjuvant-chemotherapy-for-locally-advanced-breast-cancer-different-in-sentinel-and-non-sentinel-nodes
#13
Gábor Cserni, Tamás Zombori, Xavier Andreu, Simonetta Bianchi, Peter Regitnig, Isabel Amendoeira, Davide Balmativola, Anikó Kovács, Alicia Cordoba, Angelika Reiner, Janina Kulka, Handan Kaya, Inta Liepniece-Karele, Cecily Quinn, Bence Kővári
Tumor draining sentinel lymph nodes (SLNs) are the sites of selective changes as compared to non-SLNs. They show features of tumor-reactive lymphadenopathy, including increased total number of functional blood vessels, but a relative immunosuppressed status has also been described in them. We explored the hypothesis of a selective regression or non-regression in SLNs versus non-SLNs in 142 patients with 110 estrogen receptor-positive and 32 estrogen receptor-negative tumors undergoing both SLN biopsy and axillary lymph node dissection after neoadjuvant therapy by assessing the tumoral (metastatic) and regression statuses of SLNs and non-SLNs separately...
April 8, 2017: Pathology Oncology Research: POR
https://www.readbyqxmd.com/read/28388543/thermal-tomography-for-monitoring-tumor-response-to-neoadjuvant-chemotherapy-in-women-with-locally-advanced-breast-cancer
#14
Qi Wu, Juanjuan Li, Si Sun, Xiaoli Yao, Shan Zhu, Juan Wu, Qian Liu, Xiaojun Ding, Manman Shi, Kaiyang Li, Shengrong Sun
BACKGROUND & AIMS: This study aims to analyze the feasibility and predictive value of thermal tomography (TT) for monitoring early treatment response in patients with locally advanced breast cancer (LABC) receiving neoadjuvant chemotherapy (NAC). METHODS: Patients with LABC who were due to receive six cycles of NAC were examined by TT prior to NAC, the second cycle of NAC, the fourth cycle of NAC and surgery. Changes in TT parameters and ultrasonography were correlated with pathologic response to NAC, and the predictive value was assessed...
March 25, 2017: Oncotarget
https://www.readbyqxmd.com/read/28382189/the-role-of-carboplatin-in-the-neoadjuvant-chemotherapy-treatment-of-triple-negative-breast-cancer
#15
REVIEW
Aurelio Bartolome Castrellon, Ihor Pidhorecky, Vicente Valero, Luis Estuardo Raez
Triple negative breast (TNBC) cancer constitutes a heterogeneous group of disease with histologic and molecular differences. Complete pathologic response to neoadjuvant chemotherapy (NACT) in TNBC is associated with improved outcomes. Efforts have been made in identifying drug combinations that will increase the response rate to preoperative chemotherapy. In this review we present recent studies that have incorporated carboplatin (Cb) in the NACT of TNBC. We discuss the homologous recombination deficiency score and the somatic or germline mutation for BRCA as potential biomarkers for future selection of patients that could benefit from the addition of Cb to NACT...
March 3, 2017: Oncology Reviews
https://www.readbyqxmd.com/read/28382097/oncologic-outcomes-after-immediate-breast-reconstruction-following-total-mastectomy-in-patients-with-breast-cancer-a-matched-case-control-study
#16
Jai Min Ryu, Hyun-June Paik, Sungmin Park, Ha Woo Yi, Seok Jin Nam, Seok Won Kim, Se Kyung Lee, Jonghan Yu, Soo Youn Bae, Jeong Eon Lee
PURPOSE: The use of immediate breast reconstruction (IBR) following total mastectomy (TM) has increased markedly in patients with breast cancer. As the indications for IBR have been broadened and more breast-conserving surgery-eligible patients are undergoing IBR, comparing the oncologic safety between TM only and IBR following TM becomes more difficult. This study aimed to analyze the oncologic outcomes between TM only and IBR following TM via a matched case-control methodology. METHODS: A retrospective review was conducted to identify all patients who underwent TM between 2008 and 2014...
March 2017: Journal of Breast Cancer
https://www.readbyqxmd.com/read/28381415/her2-overexpressing-breast-cancers-amplify-fgfr-signaling-upon-acquisition-of-resistance-to-dual-therapeutic-blockade-of-her2
#17
Ariella B Hanker, Joan G Garrett, Monica Valeria Estrada, Preston D Moore, Paula G Ericsson, James P Koch, Emma Langley, Sharat Singh, Phillip S Kim, Garrett M Frampton, Eric M Sanford, Philip Owns, Jennifer Becker, M Reid Groseclose, Stephen Castellino, Heikki Joensuu, Jens Huober, Jan C Brase, Majjaj Samira, Sylvain Brohée, David Venet, David Brown, José Baselga, Martine Piccart, Christos Sotiriou, Carlos L Arteaga
Dual blockade of HER2 with trastuzumab and lapatinib or pertuzumab has been shown to be superior to single-agent trastuzumab. However, a significant fraction of HER2-overexpressing (HER2+) breast cancers escape from these drug combinations. In this study, we sought to discover the mechanisms of acquired resistance to the combination of lapatinib + trastuzumab.<br /><br />Experimental Design: HER2+ BT474 xenografts were treated with lapatinib + trastuzumab long-term until resistance developed. Potential mechanisms of acquired resistance were evaluated in lapatinib + trastuzumab-resistant (LTR) tumors by targeted capture next-generation sequencing...
April 5, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28378631/tumor-infiltrating-lymphocytes-and-breast-cancer-beyond-the-prognostic-and-predictive-utility
#18
REVIEW
Andrea Ravelli, Giandomenico Roviello, Daniele Cretella, Andrea Cavazzoni, Alessandra Biondi, Maria Rosa Cappelletti, Laura Zanotti, Giuseppina Ferrero, Marco Ungari, Fabrizio Zanconati, Alberto Bottini, Roberta Alfieri, Pier Giorgio Petronini, Daniele Generali
The importance of the immune system as a potent anti-tumor defense has been consolidated in recent times, and novel immune-related therapies are today demonstrating a strong clinical benefit in the setting of several solid neoplasms. Tumor-infiltrating lymphocytes reflect the attempt of the host to eradicate malignancies, and during the last decades, they have been shown to possess an interesting prognostic utility for breast cancer, especially in case of HER2 positive and triple-negative molecular subtypes...
April 2017: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/28377213/risk-factors-and-state-of-the-art-indications-for-boost-irradiation-in-invasive-breast-carcinoma
#19
REVIEW
Alfredo Polo, Csaba Polgár, Jean-Michel Hannoun-Levi, Jose-Luis Guinot, Cristina Gutierrez, Razvan Galalae, Erik van Limbergen, Vratislav Strnad
PURPOSE: The aim of the study was to give recommendations on patient selection criteria for the administration of boost doses after whole-breast irradiation (WBI) in invasive breast cancer based on available clinical evidence complemented by expert opinion. METHODS AND MATERIALS: A systematic search of the PubMed database was conducted to identify factors associated with increased risk for local failure that can define risk groups, and to provide evidence for an adequate guidance to the use of the boost as a function of the risk of local recurrence in breast-conserving therapy...
April 1, 2017: Brachytherapy
https://www.readbyqxmd.com/read/28376176/tumor-sequencing-and-patient-derived-xenografts-in-the-neoadjuvant-treatment-of-breast-cancer
#20
Matthew P Goetz, Krishna R Kalari, Vera J Suman, Ann M Moyer, Jia Yu, Daniel W Visscher, Travis J Dockter, Peter T Vedell, Jason P Sinnwell, Xiaojia Tang, Kevin J Thompson, Sarah A McLaughlin, Alvaro Moreno-Aspitia, John A Copland, Donald W Northfelt, Richard J Gray, Katie Hunt, Amy Conners, Richard Weinshilboum, Liewei Wang, Judy C Boughey
Background: Breast cancer patients with residual disease after neoadjuvant chemotherapy (NAC) have increased recurrence risk. Molecular characterization, knowledge of NAC response, and simultaneous generation of patient-derived xenografts (PDXs) may accelerate drug development. However, the feasibility of this approach is unknown. Methods: We conducted a prospective study of 140 breast cancer patients treated with NAC and performed tumor and germline sequencing and generated patient-derived xenografts (PDXs) using core needle biopsies...
July 1, 2017: Journal of the National Cancer Institute
keyword
keyword
105931
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"